Levavi H - Search Results

1

Impact of rituximab on COVID-19 outcomes.

Levavi H, Lancman G, Gabrilove J. Levavi H, et al. Ann Hematol. 2021 Nov;100(11):2805-2812. doi: 10.1007/s00277-021-04662-1. Epub 2021 Sep 22. Ann Hematol. 2021. PMID: 34549309 Free PMC article.

2

Retrospective analysis of thiamine deficiency in allogeneic stem cell transplant patients.

Levavi H, Park D, Tannenbaum J, Steinberg A. Levavi H, et al. Ann Hematol. 2019 Jun;98(6):1499-1500. doi: 10.1007/s00277-018-3531-2. Epub 2018 Nov 3. Ann Hematol. 2019. PMID: 30392066 No abstract available.

3

Evaluating the role of Day 14 bone marrow biopsy and European LeukemiaNet risk classification in predicting overall and relapse-free survival in acute myeloid leukemia.

Balev M, Zibara V, Van Hyfte G, Feld J, Kremyanskaya M, Becker M, Keyzner A, Shih AH, Marcellino B, Levavi H, Silverman L, Mascarenhas J, Tremblay D. Balev M, et al. Among authors: levavi h. Am J Hematol. 2024 Oct;99(10):2026-2028. doi: 10.1002/ajh.27429. Epub 2024 Jul 5. Am J Hematol. 2024. PMID: 38970273

4

Immunoglobulin repletion during blinatumomab therapy does not reduce the rate of secondary hypogammaglobulinemia and associated infectious risk.

Wo S, Levavi H, Mascarenhas J, Kremyanskaya M, Navada S, Bar-Natan M, Kim SS. Wo S, et al. Among authors: levavi h. Blood Res. 2022 Jun 30;57(2):135-143. doi: 10.5045/br.2022.2021163. Epub 2022 May 13. Blood Res. 2022. PMID: 35551109 Free PMC article.

5

JAK inhibitors in the treatment of myelofibrosis.

Levavi H, Hoffman R, Marcellino BK. Levavi H, et al. Clin Adv Hematol Oncol. 2022 Jul;20(7):456-467. Clin Adv Hematol Oncol. 2022. PMID: 35802878 Review.

6

A Novel t(1;9)(p36;p24.1) JAK2 Translocation and Review of the Literature.

Levavi H, Tripodi J, Marcellino B, Mascarenhas J, Jones AV, Cross NCP, Gruenstein D, Najfeld V. Levavi H, et al. Acta Haematol. 2019;142(2):105-112. doi: 10.1159/000498945. Epub 2019 May 7. Acta Haematol. 2019. PMID: 31063994 Review.

7

Ven the dose matters: Venetoclax dosing in the frontline treatment of AML.

Sastow D, Levavi H, Wagner N, Pratz K, Tremblay D. Sastow D, et al. Among authors: levavi h. Blood Rev. 2024 Nov;68:101238. doi: 10.1016/j.blre.2024.101238. Epub 2024 Aug 29. Blood Rev. 2024. PMID: 39217050 Review.

8

A novel 3-way translocation involving ETV6::IL3 drives AML with eosinophilia.

Siegel A, Tripodi J, Hardatt D, Kelly B, El Ghaity-Beckley S, Becker M, Francisco B, Bailey K, Petersen B, Tremblay D, Feld J, Levavi H, Kremyanskaya M, Keyzner A, Marcellino BK, Salib C, Duffield AS, Mascarenhas J, Najfeld V, Shih AH. Siegel A, et al. Among authors: levavi h. Blood Neoplasia. 2025 Feb 21;2(2):100079. doi: 10.1016/j.bneo.2025.100079. eCollection 2025 May. Blood Neoplasia. 2025. PMID: 40453143 Free PMC article. No abstract available.

9

Diagnosis and management of bispecific T cell-engaging antibody toxicity: A primer for emergency physicians.

Wattana MK, Rowland J, Qdaisat A, Levavi H, Anagnostou T, Sanchez L, Friedlander P, Rohs N, Lipe DN, Richter J. Wattana MK, et al. Among authors: levavi h. Cancer Treat Rev. 2025 Mar;134:102889. doi: 10.1016/j.ctrv.2025.102889. Epub 2025 Jan 24. Cancer Treat Rev. 2025. PMID: 39913958 Review.

10

Subfertility, use of fertility treatments and BRCA mutation status and the risk of ovarian cancer.

Lerner-Geva L, Chetrit A, Farhi A, Lubin F, Sadezki S; National Israel Ovarian Cancer Study Group. Lerner-Geva L, et al. Arch Gynecol Obstet. 2022 Jul;306(1):209-217. doi: 10.1007/s00404-021-06355-6. Epub 2022 Jan 18. Arch Gynecol Obstet. 2022. PMID: 35039881

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

73 results

Search Page

Filters